TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI (IMAGE)

PLOS

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.